Neuronetics, Inc. Repayments of Long-Term Debt
Neuronetics, Inc. (STIM) reported Repayments of Long-Term Debt of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-11
- Neuronetics, Inc. repayments of long-term debt for the quarter ending 2026-06-30 was $0.00.
- Neuronetics, Inc. repayments of long-term debt for the quarter ending 2026-03-31 was $5.00M.
- Neuronetics, Inc. repayments of long-term debt for the quarter ending 2024-12-31 was $0.00.
- Neuronetics, Inc. repayments of long-term debt for the quarter ending 2023-12-31 was $0.00.
- Neuronetics, Inc. repayments of long-term debt for fiscal 2024 was $60.00M, a 4900.00% increase from fiscal 2023.
- Neuronetics, Inc. repayments of long-term debt for fiscal 2023 was $1.20M.
- Neuronetics, Inc. repayments of long-term debt for fiscal 2020 was $38.86M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.00M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $60.00M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $60.00M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $1.20M 10-K · filed 2026-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $1.20M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.20M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-07 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $6.36M derived: sum of 3 quarters · filed 2023-03-07 | $38.86M 10-K · filed 2023-03-07 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.36M derived: sum of 2 quarters · filed 2021-11-09 | $38.86M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $38.86M 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $32.50M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |